TCI Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

TCI heeft een totaal eigen vermogen van NT$8.9B en een totale schuld van NT$1.4B, wat de schuld-eigenvermogensverhouding op 15.6% brengt. De totale activa en totale passiva bedragen respectievelijk NT$14.1B en NT$5.2B. De EBIT TCI is NT$1.0B waardoor de rentedekking -22.2 is. Het heeft contanten en kortetermijnbeleggingen van NT$5.6B.

Belangrijke informatie

15.6%

Verhouding schuld/eigen vermogen

NT$1.39b

Schuld

Rente dekkingsratio	-22.2x
Contant	NT$5.63b
Aandelen	NT$8.90b
Totaal verplichtingen	NT$5.17b
Totaal activa	NT$14.08b

Recente financiële gezondheidsupdates

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

Jan 21

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$7.9B ) 8436 } overtreffen de korte termijn passiva ( NT$4.2B ).

Langlopende schulden: De kortetermijnactiva 8436 ( NT$7.9B ) overtreffen de langetermijnschulden ( NT$987.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 8436 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 8436 is de afgelopen 5 jaar gestegen van 6.7% naar 15.6%.

Schuldendekking: De schuld van 8436 wordt goed gedekt door de operationele kasstroom ( 112.1% ).

Rentedekking: 8436 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

TCI Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

Recent updates

Consensus EPS estimates increase by 13%

TCI Co., Ltd. Unveils Promising GLP-1 Formula Clinical Trial Results for Advanced Weight Management

TCI Co., Ltd. to Report Q2, 2024 Results on Jul 30, 2024

Dividend of NT$7.00 announced

New major risk - Revenue and earnings growth

TCI Co., Ltd. Approves the By-Election of Ching-Ting Chen as Institutional Director

Consensus EPS estimates increase by 16%

First quarter 2024 earnings: EPS exceeds analyst expectations

Now 21% overvalued

TCI Co., Ltd. Board Approves Dividend Distribution for the Year Ended December 31, 2023

TCI Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

TCI Co., Ltd. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS and revenues miss analyst expectations

TCI Co., Ltd., Annual General Meeting, Jun 25, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

TCI Co., Ltd. Unveils Weight Loss Formula at SupplySide West 2023

Upcoming dividend of NT$5.02 per share at 4.8% yield

TCI Co., Ltd. Announces Cash Dividend, Payable on August 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

TCI Introduces Vecollal

TCI Introduces Vecollal

Insufficient new directors

TCI Co., Ltd. Appoints Representative of the Legal Person as Director

Consensus EPS estimates fall by 26%

TCI Co., Ltd. Announces Cash Dividend for the Year Ended December 31, 2022

Now 22% undervalued

Now 20% undervalued

Price target increased by 11% to NT$179

Consensus forecasts updated

Price target increased to NT$177

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TCI Co., Ltd. Announces Executive Changes

Consensus EPS estimates fall by 31%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Upcoming dividend of NT$8.92 per share

TCI Co., Ltd. Approves Cash Dividend, Payable on August 18, 2022

Price target decreased to NT$183

TCI Co., Ltd. Appoints Members of the Risk Management Committee

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Price target decreased to NT$197

TCI Co., Ltd., Annual General Meeting, Jun 29, 2022

Price target decreased to NT$197

Consensus EPS estimates fall by 13%

Price target decreased to NT$258

Price target decreased to NT$278

Price target decreased to NT$283

Third quarter 2021 earnings released: EPS NT$4.02 (vs NT$4.23 in 3Q 2020)

Upcoming dividend of NT$8.88 per share

Second quarter 2021 earnings released: EPS NT$4.19 (vs NT$4.50 in 2Q 2020)

Investor sentiment improved over the past week

TCI Co., Ltd. (TPEX:8436) entered into a memorandum of understanding to acquire US manufacturing operations from NewAge, Inc. (NasdaqCM:NBEV) for $3.5 million.

Head of Finance Department & CFO Chia- Chi Li has left the company

Price target increased to NT$249

Price target increased to NT$240

First quarter 2021 earnings released: EPS NT$3.25 (vs NT$3.13 in 1Q 2020)

Is TCI Co., Ltd. (GTSM:8436) A Smart Choice For Dividend Investors?

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$15.69 (vs NT$17.02 in FY 2019)

Analysts lower EPS estimates to NT$15.17

TCI Co., Ltd. (GTSM:8436) made an offer to acquire 30% stake in Maxigen Biotech Inc. (TSEC:1783) for approximately TWD 600 million.

Price target lowered to NT$235

Full year 2020 earnings released: EPS NT$15.69 (vs NT$17.02 in FY 2019)

Revenue and earnings miss expectations

New 90-day high: NT$221

Is TCI's (GTSM:8436) 160% Share Price Increase Well Justified?

We Think TCI (GTSM:8436) Can Stay On Top Of Its Debt

New 90-day low: NT$197

Is TCI (GTSM:8436) The Next Multi-Bagger?

New 90-day low: NT$209

Did You Participate In Any Of TCI's (GTSM:8436) Incredible 308% Return?